Infectious Disease, Respirology
Webinar: RSV Prevention for All Infants
This 60-minute webinar is designed to provide Canadian HCPs with practical information on passive immunization options available in Canada, with a focus on the newly authorized long-acting monoclonal antibody nirsevimab, and the maternal RSVpref vaccine. The webinar will discuss RSV prevention through case studies, and highlight how a hospital order set can support implementation of the new RSV immunoprophylaxis in clinical practice.
DURATION
1 hr
PROFESSION
Physician, Nursing, Pharmacy, Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2025-06-10
Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV is also the leading cause of infant hospitalizations in Canada, resulting in significant disease burden and impacts on the Canadian health system. Considering the substantial burden of disease on all infants, NACI has recently issued new recommendations towards a universal RSV immunization program, with the use of nirsevimab to prevent severe RSV disease. In 2023, two new products were authorized by Health Canada for use in RSV immunization programs: nirsevimab, a long-acting monoclonal antibody, and RSVpref, a maternal vaccine. The available efficacy (including duration of protection) and safety data for RSVpreF and nirsevimab underpin NACI’s preferential recommendation for nirsevimab.
This program has received an unrestricted educational grant or in-kind support from Sanofi.
Faculty
Erin Fleischer, RN (EC) NP Paeds, BSCN, MN, ACNP
Marc Lebel, MD, FRCPC
Taj Jadavji, MD, FRCPC, FAAP
Learning objectives
Upon completion of this program, participants will be able to:
- Describe the prevalence and burden of RSV disease in all infants
- Summarize NACI guidance and supporting evidence on passive immunization for RSV
- Implement a hospital order set for RSV
prevention to support clinical practice
#
of credits: 0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Physician, Nursing, Pharmacy, Specialist
Profession
0
# of credits
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe the prevalence and burden of RSV disease in all infants
- Summarize NACI guidance and supporting evidence on passive immunization for RSV
- Implement a hospital order set for RSV
prevention to support clinical practice
Unaccredited
ACCREDITATION
Infectious Disease, Respirology
Learning Category
Respiratory
Topic
0
Price
2025-06-10
Expiry Date
CAN-eng
Region/Language
Course Description
Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV is also the leading cause of infant hospitalizations in Canada, resulting in significant disease burden and impacts on the Canadian health system. Considering the substantial burden of disease on all infants, NACI has recently issued new recommendations towards a universal RSV immunization program, with the use of nirsevimab to prevent severe RSV disease. In 2023, two new products were authorized by Health Canada for use in RSV immunization programs: nirsevimab, a long-acting monoclonal antibody, and RSVpref, a maternal vaccine. The available efficacy (including duration of protection) and safety data for RSVpreF and nirsevimab underpin NACI’s preferential recommendation for nirsevimab.
This program has received an unrestricted educational grant or in-kind support from Sanofi.
Faculty
Erin Fleischer, RN (EC) NP Paeds, BSCN, MN, ACNP
Marc Lebel, MD, FRCPC
Taj Jadavji, MD, FRCPC, FAAP
Accreditation
1 hr
Duration
0
Price
0
# of credits
